RESISTANCE MUTATIONS TO INTEGRASE INHIBITORS AND HIV-1 SUBTYPES IN PREGNANT WOMEN LIVING WITH HIV IN RIO DE JANEIRO, 2018–2024
Introduction: Since 2017, dolutegravir (DTG), a second-generation integrase inhibitor (INI) with a high genetic barrier, has been part of first-line HIV treatment together with tenofovir and lamivudine. Resistance mutations (RMs) to this regimen are rare. In a recent systematic review, RM rates amon...
Guardat en:
| Autors principals: | , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Elsevier
2026-03-01
|
| Col·lecció: | Brazilian Journal of Infectious Diseases |
| Matèries: | |
| Accés en línia: | http://www.sciencedirect.com/science/article/pii/S1413867026002278 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|